Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Chabot

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Anti-Cancer Drugs|February 1, 1996
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patientsD Abigerges, J P Armand, G G Chabot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Cancer Research|August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patientsM de Forni, R Bugat, G G Chabot, et al.
Cancer Research|April 1, 1993
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor modelJ N Munck, M Riggi, P Rougier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastasesJ N Munck, P Rougier, G G Chabot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I/II trial of continuous infusion vinorelbine for advanced breast cancerC Toussaint, J Izzo, M Spielmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsG G Chabot, D Abigerges, G Catimel, et al.
International Journal of Pharmaceutics|February 6, 2013
Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacyJohanne Seguin, Laura Brullé, Renaud Boyer, et al.
Bioorganic & Medicinal Chemistry Letters|September 6, 2011
Ferrocenyl chalcone difluoridoborates inhibit HIV-1 integrase and display low activity towards cancer and endothelial cellsJean-Philippe Monserrat, Rasha I Al-Safi, Keshri Nath Tiwari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I studyG G Chabot, J P Armand, C Terret, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Anti-Cancer Drugs|February 1, 1996
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patientsD Abigerges, J P Armand, G G Chabot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Cancer Research|August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patientsM de Forni, R Bugat, G G Chabot, et al.
Cancer Research|April 1, 1993
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor modelJ N Munck, M Riggi, P Rougier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastasesJ N Munck, P Rougier, G G Chabot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I/II trial of continuous infusion vinorelbine for advanced breast cancerC Toussaint, J Izzo, M Spielmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsG G Chabot, D Abigerges, G Catimel, et al.
International Journal of Pharmaceutics|February 6, 2013
Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacyJohanne Seguin, Laura Brullé, Renaud Boyer, et al.
Bioorganic & Medicinal Chemistry Letters|September 6, 2011
Ferrocenyl chalcone difluoridoborates inhibit HIV-1 integrase and display low activity towards cancer and endothelial cellsJean-Philippe Monserrat, Rasha I Al-Safi, Keshri Nath Tiwari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I studyG G Chabot, J P Armand, C Terret, et al.
Pageof 18